Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 3.5% – What’s Next?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s stock price dropped 3.5% during mid-day trading on Friday . The company traded as low as $0.29 and last traded at $0.30. Approximately 25,356,621 shares changed hands during trading, a decline of 38% from the average daily volume of 41,203,656 shares. The stock had previously closed at $0.31.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on Tonix Pharmaceuticals in a research note on Wednesday. They issued a “hold” rating on the stock.

Tonix Pharmaceuticals Trading Down 5.3 %

The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07. The firm’s 50-day moving average is $0.24 and its 200-day moving average is $0.37. The firm has a market cap of $55.60 million, a price-to-earnings ratio of -0.01 and a beta of 2.23.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.03) by $1.80. The company had revenue of $2.82 million for the quarter, compared to analyst estimates of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. As a group, sell-side analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current fiscal year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.